Výsledky vyhledávání - "Nguyet Le‐Lindqwister"

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Autor: Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, Päivi Auvinen, Catarina Pulido, Ana Cvetanovic, Sharon Wilks, Leonor Ribeiro, Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, Ari Alexandrou, Peter Trask, Judy Fredriksson, Zuzana Machackova, Ljiljana Stamatovic, Ernesto Korbenfeld, Jorge Nadal, Helio Pinczowski, Felipe J. Cruz, Gustavo Sousa, Aline C. Goncalves, Gisah Guilgen, Antti Jekunen, Winne Yeo, Chi K. Cheng, Hikmat A. Razeq, Fadi Karak, Fadi Farhat, Servando C. Huerta, Brizio M. Jaime, Juan Feregrino, Omar Castillo-Fernandez, Juan C. Alcedo, Maria Dionisio, Salha Bujassoum, Hatoon Bakhraibah, Alvaro R. Lescure, Camilla Wendt, Sara Margolin, Helena G. Björneklett, Michelina Cairo, Shaker Dakhil, Nguyet Le-Lindqwister, Ling Ma, Kristi J. McIntyre, Joyce O’Shaughnessy, Svetislava J. Vukelja, Donald Richards, John Wallmark

Aim: The aim of the study was to assess patient preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients with HER2-positive early breast cancer in PHranceSCa (NCT03674112). Materials a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa4c6a666e370a233289e49fa120291
https://zenodo.org/record/5196150

Zobrazit plný text záznamu

A pragmatic cluster-randomized trial of a standing physician order entry intervention for colony stimulating factor use among patients at intermediate risk for febrile neutropenia (SWOG S1415CD)

Autor: Dawn L. Hershman, Aasthaa Bansal, Sean D Sullivan, Gary H. Lyman, William E. Barlow, Kathryn B. Arnold, Kate Watabayashi, Ari Bell-Brown, Nguyet Le-Lindqwister, Carrie L. Dul, Ursa Brown-Glaberman, Robert J. Behrens, Victor G. Vogel, Nitya Alluri, Scott David Ramsey

Publikováno v: Journal of Clinical Oncology. 40:1518-1518

1518 Background: Primary prophylactic colony stimulating factors (PP-CSF) are prescribed to patients undergoing chemotherapy to reduce the risk of febrile neutropenia (FN) but their benefit for regimens with intermediate FN risk is uncertain. Within

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b535e451dcfed01b34f8d74c96ee17e
https://doi.org/10.1200/jco.2022.40.16_suppl.1518

Zobrazit plný text záznamu

A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for patients with cancer receiving myelosuppressive chemotherapy (SWOG S1415CD)

Autor: Scott David Ramsey, Aasthaa Bansal, Sean D. Sullivan, Gary H. Lyman, William E. Barlow, Kathryn B. Arnold, Kate Watabayashi, Ari Bell-Brown, Nguyet Le-Lindqwister, Carrie L. Dul, Ursa Brown-Glaberman, Robert J. Behrens, Victor G. Vogel, Nitya Alluri, Dawn L. Hershman

Publikováno v: Journal of Clinical Oncology. 40:1525-1525

1525 Background: Primary prophylactic colony stimulating factors (PP-CSF) are prescribed to patients undergoing chemotherapy to reduce the risk of febrile neutropenia (FN). Prior studies have shown that 55-95% of CSF prescribing is inconsistent with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc2cb8abd71c2c84cb9606bbc3027636
https://doi.org/10.1200/jco.2022.40.16_suppl.1525

Zobrazit plný text záznamu

Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature

Autor: James A. Knost, Vincent A. Miller, Srinivas Jujjavarapu, Nguyet Le‐Lindqwister, Alexa B. Schrock, Lauren M. Thorpe, Siraj M. Ali, Rachel L. Erlich, Jane Liu

Publikováno v: Headneck. 39(3)

Background Salivary ductal carcinoma and carcinoma ex pleomorphic adenoma (CEPA) are aggressive salivary gland cancers with poor prognosis. The standard of care is resection with or without radiotherapy, and there are no established systemic therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af602b3cc6bc5e74229ea6a06692d183
https://pubmed.ncbi.nlm.nih.gov/28006087

Zobrazit plný text záznamu

Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy

Autor: Tim A. Ahles, Stewart B. Fleishman, Nguyet Le-Lindqwister, Electra D. Paskett, Linda R. Bressler, Herbert Pang, Chetaye Knox, Paul Gilman, Camilo E. Fadul, Ellen M. Lavoie Smith, Constance Cirrincione, Charles L. Shapiro

Publikováno v: JAMA. 309:1359

Importance There are no known effective treatments for painful chemotherapy-induced peripheral neuropathy. Objective To determine the effect of duloxetine, 60 mg daily, on average pain severity. Design, Setting, and Patients Randomized, double-blind,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a226ea3fa3c7c835b63df6aeecf0e066
https://doi.org/10.1001/jama.2013.2813

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání